Navigating comorbidities and polypharmacy in mHSPC: Real-World Differentiation and Clinical Outcomes - European Medical Journal

This site is intended for healthcare professionals

Navigating comorbidities and polypharmacy in mHSPC: Real-World Differentiation and Clinical Outcomes

Oncology

This project is intended for HCPs and has been funded by Bayer and fully created by EMJ.

This video podcast covers the current treatment landscape for mHSPC and covers the burden of comorbidities and polypharmacy. Our experts then dive deeper into several case based scenarios which are seen in practice and provide the clinical expertise on what to consider and how to best manage these hypothetical patient cases.

Speakers

Daniel George1


Alicia Morgans2


Christian Gratzke3


1. Department of Medicine, Duke University School of Medicine, Durham, North Carolina, US.
2. Harvard Medical School, Boston, Massachusetts, US.
3. Department of Urology, Center for Surgery at the Medical Center – University of Freiburg, Germany.

Moderator

Jessica Jinks4


4. EMJ, UK

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.